Aurinia Pharmaceuticals (NASDAQ:AUPH) Rating Lowered to Buy at StockNews.com

StockNews.com lowered shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) from a strong-buy rating to a buy rating in a research report sent to investors on Wednesday morning.

Aurinia Pharmaceuticals Trading Up 1.2 %

NASDAQ AUPH opened at $7.93 on Wednesday. The company has a quick ratio of 5.11, a current ratio of 5.60 and a debt-to-equity ratio of 0.17. The firm has a market capitalization of $1.13 billion, a PE ratio of -52.83 and a beta of 1.22. The stock’s 50 day moving average is $8.33 and its 200 day moving average is $7.68. Aurinia Pharmaceuticals has a twelve month low of $4.71 and a twelve month high of $10.67.

Institutional Investors Weigh In On Aurinia Pharmaceuticals

Hedge funds have recently bought and sold shares of the business. Tang Capital Management LLC boosted its position in shares of Aurinia Pharmaceuticals by 16.6% in the 4th quarter. Tang Capital Management LLC now owns 8,429,500 shares of the biotechnology company’s stock worth $75,697,000 after purchasing an additional 1,200,000 shares in the last quarter. State Street Corp lifted its stake in shares of Aurinia Pharmaceuticals by 2.3% in the third quarter. State Street Corp now owns 2,945,060 shares of the biotechnology company’s stock worth $21,587,000 after buying an additional 64,949 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Aurinia Pharmaceuticals by 6.9% during the fourth quarter. Vanguard Group Inc. now owns 1,729,948 shares of the biotechnology company’s stock valued at $15,535,000 after acquiring an additional 112,113 shares in the last quarter. Nuveen Asset Management LLC raised its holdings in Aurinia Pharmaceuticals by 10.2% in the 4th quarter. Nuveen Asset Management LLC now owns 1,492,301 shares of the biotechnology company’s stock worth $13,401,000 after acquiring an additional 138,054 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership bought a new position in Aurinia Pharmaceuticals in the 4th quarter valued at approximately $9,662,000. Institutional investors own 36.83% of the company’s stock.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.